Danaher Corporation $DHR Stock Holdings Decreased by Handelsbanken Fonder AB

Handelsbanken Fonder AB lowered its position in shares of Danaher Corporation (NYSE:DHR) by 10.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 232,282 shares of the conglomerate’s stock after selling 28,377 shares during the quarter. Handelsbanken Fonder AB’s holdings in Danaher were worth $45,885,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Nuveen LLC purchased a new stake in shares of Danaher in the first quarter valued at $833,941,000. Generation Investment Management LLP lifted its stake in Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after acquiring an additional 1,787,522 shares in the last quarter. Invesco Ltd. boosted its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the period. Primecap Management Co. CA boosted its position in Danaher by 924.2% during the 2nd quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after acquiring an additional 1,118,318 shares during the period. Finally, Baird Financial Group Inc. grew its stake in Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after acquiring an additional 1,072,617 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 2.3%

Danaher stock opened at $227.34 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company’s fifty day moving average price is $208.58 and its two-hundred day moving average price is $201.97. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The company has a market capitalization of $160.58 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.71 earnings per share. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is presently 26.39%.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This trade represents a 59.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 over the last 90 days. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of several research reports. Robert W. Baird set a $247.00 price target on shares of Danaher in a report on Wednesday, October 22nd. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Barclays boosted their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Cowen reiterated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Finally, TD Cowen lifted their price objective on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.